Dark Forest Capital Management LP Grows Stock Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Dark Forest Capital Management LP lifted its holdings in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 132.4% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 10,249 shares of the company’s stock after purchasing an additional 5,839 shares during the quarter. Dark Forest Capital Management LP’s holdings in Kymera Therapeutics were worth $412,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Wellington Management Group LLP lifted its stake in Kymera Therapeutics by 14.9% in the fourth quarter. Wellington Management Group LLP now owns 5,307,326 shares of the company’s stock worth $213,514,000 after acquiring an additional 688,967 shares during the last quarter. Avoro Capital Advisors LLC increased its holdings in Kymera Therapeutics by 14.4% in the fourth quarter. Avoro Capital Advisors LLC now owns 5,150,000 shares of the company’s stock valued at $207,184,000 after buying an additional 650,000 shares during the last quarter. Vanguard Group Inc. raised its stake in Kymera Therapeutics by 2.8% in the fourth quarter. Vanguard Group Inc. now owns 4,887,312 shares of the company’s stock valued at $196,617,000 after buying an additional 133,546 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Kymera Therapeutics by 5.0% during the 4th quarter. Geode Capital Management LLC now owns 1,105,487 shares of the company’s stock worth $44,484,000 after buying an additional 52,263 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its position in shares of Kymera Therapeutics by 5.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 387,187 shares of the company’s stock worth $15,577,000 after acquiring an additional 20,346 shares in the last quarter.

Insider Buying and Selling

In related news, insider Ellen Chiniara sold 2,241 shares of the business’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $30.45, for a total transaction of $68,238.45. Following the transaction, the insider now directly owns 80,085 shares of the company’s stock, valued at approximately $2,438,588.25. The trade was a 2.72 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CFO Bruce N. Jacobs sold 7,035 shares of the company’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $30.45, for a total value of $214,215.75. Following the completion of the transaction, the chief financial officer now owns 201,886 shares of the company’s stock, valued at approximately $6,147,428.70. This represents a 3.37 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 10,659 shares of company stock valued at $324,567. Company insiders own 15.82% of the company’s stock.

Kymera Therapeutics Price Performance

NASDAQ KYMR opened at $33.26 on Monday. Kymera Therapeutics, Inc. has a 1-year low of $19.45 and a 1-year high of $53.27. The firm has a market capitalization of $2.16 billion, a P/E ratio of -14.21 and a beta of 2.22. The business’s 50-day simple moving average is $29.89 and its 200-day simple moving average is $38.54.

Kymera Therapeutics (NASDAQ:KYMR) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.76) by ($0.12). Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. The business had revenue of $7.39 million for the quarter, compared to analysts’ expectations of $14.81 million. On average, equities research analysts expect that Kymera Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages have commented on KYMR. HC Wainwright increased their price target on shares of Kymera Therapeutics from $54.00 to $60.00 and gave the company a “buy” rating in a research note on Friday, February 28th. Citigroup assumed coverage on shares of Kymera Therapeutics in a research note on Thursday, March 13th. They issued a “buy” rating and a $52.00 price objective for the company. Finally, Stephens reaffirmed an “overweight” rating and set a $60.00 price objective on shares of Kymera Therapeutics in a report on Tuesday, January 21st. Three equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $56.36.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.